ArticleFrontiers in aging neuroscience2018
A Specific Reduction in Aβ
Article in Frontiers in aging neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Causal Effects of the Plasma Proteome on Vascular Dementia Risk: A Mendelian Randomization Study with Experimental Validation.Cellular and molecular neurobiology · 2025Article
- Unveiling the Therapeutic Potential of Kelulut (Stingless Bee) Honey in Alzheimer's Disease: Findings from a Rat Model Study.Antioxidants (Basel, Switzerland) · 2024Article
- Amyloid and Tau as cerebrospinal fluid biomarkers in anti-N-Methyl-D-aspartate receptor encephalitis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score.Journal of Alzheimer's disease : JAD · 2023Article
- Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.Brain : a journal of neurology · 2022Observational
- Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.Biomedicines · 2022Review
- Article
- Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines.Frontiers in immunology · 2020Article
- CD8+ T Cell-Mediated Mechanisms Contribute to the Progression of Neurocognitive Impairment in Both Multiple Sclerosis and Alzheimer's Disease?Frontiers in immunology · 2020Review
- Characterization of Cerebrospinal Fluid BACE1 Species.Molecular neurobiology · 2019Article
- APP-derived peptides reflect neurodegeneration in frontotemporal dementia.Annals of clinical and translational neurology · 2019Article
- Enteroviral meningitis reduces CSF concentration of Aβ42, but does not affect markers of parenchymal damage.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Antemortem CSF AAnnals of clinical and translational neurology · 2019Article
- Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?Dialogues in clinical neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A reduced concentration of Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.